期刊
JOURNAL OF SURGICAL ONCOLOGY
卷 112, 期 6, 页码 597-602出版社
WILEY
DOI: 10.1002/jso.24050
关键词
neoadjuvant chemotherapy; complete pathologic response; esophageal cancer; staging systems; treatment guidelines; lymph node metastasis
BackgroundThe prognostic significance of residual nodal disease in otherwise complete pathologic responders (ypT0N+) to neoadjuvant chemoradiation (nCRT) for esophageal cancer is unknown. MethodsypT0N+ responders were identified from a single institution database of esophageal cancer patients undergoing esophagectomy and were compared to patients without locoregional disease (ypT0N0) and to non-complete responders (ypT+). ResultsOut of 487 patients, 196 ypT0N0 and 14 ypT0N+ patients were identified. Pre-treatment stage was similar between ypT0N0 and ypT0N+ patients: 66% versus 73% of patients had uT3 disease (P=0.50) and 76% versus 55% had nodal involvement (P=0.49), respectively. Locoregional recurrence (43%) was more common in ypT0N+ patients. Median overall survival (OS) was worse in ypT0N+ patients (14.8 months) compared to ypT0N0 patients (92.2 months) and ypT+ patients (38.0 months, P<0.001). Median OS of ypT0N+ patients was similar to ypT+ stage II (29.6 months, P=0.84) and stage III (27.5 months, P=0.95) disease. No difference in median OS existed in patients with residual nodal disease (n=163) based on local response (14.8 months in ypT0N+ and 22.5 months in ypT+N+ patients, P=0.55). ConclusionsResidual nodal disease in esophageal cancer patients with complete response in the primary tumor following nCRT portends a poor prognosis and behaves similar to pathologic stage II/III disease. J. Surg. Oncol. 2015;112:597-602. (c) 2015 Wiley Periodicals, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据